The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor compound, alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://cormaclijp244837.digitollblog.com/41741977/retatrutide-and-nad-a-triple-threat-approach-to-metabolic-wellness